Evidence map›Paper›PMID 42015695›Full record

ArticleZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2026

[Safety of blinatumomab combined with dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia].

Fang-Yuan Zheng, Ming-Ming Ding, Ai-Dong Lu, Yue-Ping Jia, Hui-Min Zeng, Le-Ping Zhang

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fang-Yuan ZhengDepartment of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
Ming-Ming DingDepartment of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
Ai-Dong LuDepartment of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
Yue-Ping JiaDepartment of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
Hui-Min ZengDepartment of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
Le-Ping ZhangDepartment of Pediatrics, Peking University People's Hospital, Beijing 100044, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the safety of blinatumomab combined with dasatinib in children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph

methodsA retrospective review was conducted of clinical data for children with Ph

resultsTen children were included (7 boys, 3 girls), with a total of 13 instances of combination therapy. After treatment,

conclusionsBlinatumomab combined with dasatinib is well tolerated in pediatric Ph

Indexed as

Antibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsDasatinibPhiladelphia ChromosomePrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleHumansInfantMaleRetrospective StudiesAntibodies, BispecificblinatumomabDasatinibAcute lymphoblastic leukemiaBlinatumomabChildDasatinibPhiladelphia chromosome-positive

Identifiers

PMID42015695
PMCPMC13108949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.